• 1
    Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999; 91: 111324.
  • 2
    Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342: 52533.
  • 3
    Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jager W. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 2001; 19: 366974.
  • 4
    Gerber B, Krause A, Muller H, Richter D, Reimer T, Makovitzky J, Herrnring C, Jeschke U, Kundt G, Friese K. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 2001; 19: 96071.
  • 5
    Braun S, Pantel K. Biological characteristics of micrometastatic cancer cells in bone marrow. Cancer Metastasis Rev 1999; 18: 7590.
  • 6
    Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR, Riethmuller G. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci USA 1999; 96: 44949.
  • 7
    Klein CA. The biology and analysis of single disseminated tumour cells. Trends Cell Biol 2000; 10: 48993.
  • 8
    Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 122.
  • 9
    Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 93243.
  • 10
    Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991; 266: 192633.
  • 11
    Ploug M, Ellis V. Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett 1994; 349: 1638.
  • 12
    Busso N, Masur SK, Lazega D, Waxman S, Ossowski L. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol 1994; 126: 25970.
  • 13
    Xue W, Mizukami I, Todd RF 3rd, Petty HR. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res 1997; 57: 16829.
  • 14
    Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Hofler H, Janicke F, Graeff H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997; 78: 28596.
  • 15
    Hemsen A, Riethdorf L, Brunner N, Berger J, Ebel S, Thomssen C, Janicke F, Pantel K. Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells. Int J Cancer 2003; 107: 9039.
  • 16
    Memarzadeh S, Kozak KR, Chang L, Natarajan S, Shintaku P, Reddy ST, Farias-Eisner R, Memarzedeh S. Urokinase plasminogen activator receptor: prognostic biomarker for endometrial cancer. Proc Natl Acad Sci USA 2002; 99: 1064752.
  • 17
    Grondahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Ronne E, Dano K, Klijn JG, Brunner N, Foekens JA. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995; 1: 107987.
  • 18
    Bouchet C, Hacene K, Martin PM, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F. Dissemination risk index based on plasminogen activator system components in primary breast cancer. J Clin Oncol 1999; 17: 304857.
  • 19
    de Witte JH, Foekens JA, Brunner N, Heuvel JJ, van Tienoven T, Look MP, Klijn JG, Geurts-Moespot A, Grebenchtchikov N, Benraad T, Sweep CG. Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br J Cancer 2001; 85: 8592.
  • 20
    Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1995; 1: 10359.
  • 21
    Heiss MM, Simon EH, Beyer BC, Gruetzner KU, Tarabichi A, Babic R, Schildberg FW, Allgayer H. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. J Clin Oncol 2002; 20: 200516.
  • 22
    Allgayer H, Heiss MM, Riesenberg R, Grutzner KU, Tarabichi A, Babic R, Schildberg FW. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res 1997; 57: 13949.
  • 23
    Borgfeldt C, Bendahl PO, Gustavsson B, Langstrom E, Ferno M, Willen R, Grenman S, Casslen B. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer. Int J Cancer 2003; 107: 65865.
  • 24
    Gottlinger HG, Funke I, Johnson JP, Gokel JM, Riethmuller G. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 1986; 38: 4753.
  • 25
    International Union Against Cancer. Breast tumours. In: Wiley-Liss Inc., ed. TNM classification of malignant tumours, 5th ed. New-York: 1997. 12330.
  • 26
    Trempe GL. Human breast cancer in culture. Recent Results Cancer Res 1976; 57: 3341.
  • 27
    Pierga JY, Bonneton C, Magdelénat H, Vincent-Salomon A, Nos C, Pouillart P, Thiery JP. Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer. Br J Cancer 2003; 89: 53945.
  • 28
    Van der Loos CM, Das PK, Van den Oord JJ, Houthoff HJ. Multiple immunoenzyme staining techniques. Use of fluoresceinated, biotinylated and unlabelled monoclonal antibodies. J Immunol Methods 1989; 117: 4552.
  • 29
    de Crémoux P, Extra JM, Denis MG, Pierga JY, Bourstyn E, Nos C, Clough KB, Boudou E, Martin EC, Muller A, Pouillart P, Magdelenat, H. Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. Clin Cancer Res 2000; 6: 311722.
  • 30
    Vincent-Salomon A, Jouve M, Genin P, Freneaux P, Sigal-Zafrani B, Caly M, Beuzeboc P, Pouillart P, Sastre-Garau X. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002; 94: 216973.
  • 31
    Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S, Bastert G. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996; 88: 16528.
  • 32
    Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 1999; 354: 197202.
  • 33
    Braun S, Vogl F, Schlimok G, Diel IJ, Janni W, Gerber B, Gebauer G, Coombes, Pantel K. Pooled analysis of prognostic impact of occult metastatic cells (OMC) in bone marrow: 10-year survival of 3448 breast cancer patients. Proc Am Soc Clin Oncol 2003; 22: A3402.
  • 34
    Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O, Wendler N, Passlick B, Huber RM, Schlimok G, Baeuerle PA, Riethmuller G. Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol 2002; 20: 38792.
  • 35
    Hosch SB, Braun S, Pantel K. Characterization of disseminated tumor cells. Semin Surg Oncol 2001; 20: 26571.
  • 36
    Werther K, Normark M, Hansen BF, Nielsen HJ. Immunoglobulin and enzyme-conjugated dextran polymers enhance u-PAR staining intensity of carcinoma cells in peripheral blood smears. J Histochem Cytochem 1999; 47: 95964.
  • 37
    Togel F, Datta C, Badbaran A, Kroger N, Renges H, Gieseking F, Janicke F, Zander AR, Kruger W. Urokinase-like plasminogen activator receptor expression on disseminated breast cancer cells. J Hematother Stem Cell Res 2001; 10: 1415.
  • 38
    Noack F, Helmecke D, Rosenberg R, Thorban S, Nekarda H, Fink U, Lewald J, Stich M, Schutze K, Harbeck N, Magdolen V, Graeff H, et al. CD87-positive tumor cells in bone marrow aspirates identified by confocal laser scanning fluorescence microscopy. Int J Oncol 1999; 15: 61723.
  • 39
    Noack F, Schmitt M, Bauer J, Helmecke D, Kruger W, Thorban S, Sandherr M, Kuhn W, Graeff H, Harbeck N. A new approach to phenotyping disseminated tumor cells: methodological advances and clinical implications. Int J Biol Markers 2000; 15: 1004.
  • 40
    Nakata S, Ito K, Fujimori M, Shingu K, Kajikawa S, Adachi W, Matsuyama I, Tsuchiya S, Kuwano M, Amano J. Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers. Int J Cancer 1998; 79: 17986.
  • 41
    Konno H, Baba M, Shoji T, Ohta M, Suzuki S, Nakamura S. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis 2002; 19: 52734.
  • 42
    Fisher JL, Field CL, Zhou H, Harris TL, Henderson MA, Choong PF. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases—a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res Treat 2000; 61: 112.
  • 43
    Foca C, Moses EK, Quinn MA, Rice GE. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas. Gynecol Oncol 2000; 79: 24450.
  • 44
    Li Y, Wood N, Yellowlees D, Donnelly PK. Cell surface expression of urokinase receptor in normal mammary epithelial cells and breast cancer cell lines. Anticancer Res 1999; 19: 12238.
  • 45
    Hildenbrand R, Glienke W, Magdolen V, Graeff H, Stutte HJ, Schmitt M. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry. Histochem Cell Biol 1998; 110: 2732.
  • 46
    Dubuisson L, Monvoisin A, Nielsen BS, Le Bail B, Bioulac-Sage P, Rosenbaum J. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma. J Pathol 2000; 190: 1905.
  • 47
    Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001; 12: 86379.
  • 48
    Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003; 63: 168495.
  • 49
    Rabbani SA, Gladu J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 2002; 62: 23907.